GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunic Inc (STU:10VA) » Definitions » YoY EPS Growth

Immunic (STU:10VA) YoY EPS Growth : 49.08% (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Immunic YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Immunic's YoY EPS Growth for the quarter that ended in Mar. 2024 was 49.08%.

Immunic's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was €-0.28.

Immunic YoY EPS Growth Historical Data

The historical data trend for Immunic's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunic YoY EPS Growth Chart

Immunic Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 88.19 43.22 -50.56 -2.59 45.77

Immunic Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.35 26.87 31.42 71.22 49.08

Immunic YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Immunic's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EPS Growth (A: Dec. 2023 )
=(Earnings per Share (Diluted) (A: Dec. 2023 )-Earnings per Share (Diluted) (A: Dec. 2022 ))/ | Earnings per Share (Diluted) (A: Dec. 2022 ) |
=(-1.935--3.568)/ | -3.568 |
=45.77 %

Immunic's YoY EPS Growth for the quarter that ended in Mar. 2024 is calculated as:

YoY EPS Growth (Q: Mar. 2024 )
=(Earnings per Share (Diluted) (Q: Mar. 2024 )-Earnings per Share (Diluted) (Q: Mar. 2023 )) / | Earnings per Share (Diluted) (Q: Mar. 2023 )) |
=(-0.276--0.542)/ | -0.542 |
=49.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunic YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Immunic's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunic (STU:10VA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunic Inc (STU:10VA) » Definitions » YoY EPS Growth
Comparable Companies
OKYO MEIP SPRB MTNB LGVN ASMB DYAI EYEN AGLE TIL OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
IMUX:USA 10VA:Germany
Address
1200 Avenue of the Americas, Suite 200, New York, NY, USA, 10036
Website
https://www.imux.com
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Immunic (STU:10VA) Headlines

No Headlines